DERMOMYCIN ® Fusidic acid

DERMOMYCIN ® is a drug based on fusidic acid sodium salt

THERAPEUTIC GROUP: Antibiotics for topical use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications DERMOMYCIN ® Fusidic acid

DERMOMYCIN ® is indicated in the treatment of skin infections caused by bacteria sensitive to fusidic acid.

Mechanism of action DERMOMYCIN ® Fusidic acid

Sodium fusidate, the sodium salt of fusidic acid and the active ingredient of DERMOMYCIN ®, is a steroid molecule with marked antibiotic activity, especially effective against Gram positive organisms such as Staphylococcus aureus.

Its chemical structure allows the fusidic acid applied topically to easily penetrate the bacterial membranes, reaching and complexing protein factors such as the elongation factor G, important in facilitating the elongation of the nascent peptide chain.

The blocking of protein synthesis on the one hand and the consequent lack of enzymatic factors and structural proteins on the other, considerably limits the vitality of the micro-organism, inducing its death and therefore the remission of the complained symptomatology.

Studies carried out and clinical efficacy

FUSID ACID IN DERMATOLOGY

Eur J Dermatol. 2010 Jan-Feb; 20 (1): 6-15. doi: 10.1684 / ejd.2010.0833. Epub 2009 Dec 14.

Review of dermatological interest that reaffirms the importance of fusidic acid in the treatment of bacterial infections also sustained by generally resistant microorganisms, and the combination with betamethasone for the treatment of eczema.

FUSIDIC ACID / BETAMETHASONE IN THE TREATMENT OF ATOPIC DERMATITIS

Acta Derm Venereol. 2007; 87 (1): 62-8.

Work that demonstrates the effectiveness of the combination fusidic acid / betamethasone in the treatment of atopic dermatitis, guaranteeing in a few weeks of treatment a significant remission of symptoms.

FUSIDIC ACID IN THE TREATMENT OF IMPETIGINE

BMJ. 2002 Jan 26; 324 (7331): 203-6.

Randomized clinical trial that demonstrates the greater efficacy of fusidic acid than placebo in the treatment of impetigo, and is also very well tolerated from the clinical point of view.

Method of use and dosage

DERMOMYCIN ®

20 mg cream of Fusidate of sodium per gr of solution.

Always according to medical prescription it is generally recommended to apply the appropriate quantity of medicine directly on the region affected by the infectious process 2-3 times a day.

Warnings DERMOMYCIN ® Fusidic acid

The correct use of DERMOMYCIN ®, as well as that of other antibiotics for topical use, necessarily requires compliance with different sanitary regulations useful to limit the incidence of potential side effects and to optimize therapeutic efficacy.

However, it is important to remember that the prolonged use of antibiotics may favor the incidence of local adverse reactions and the spread of generally resistant microbial strains, such as to complicate the clinical situation.

It is advisable to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

Given the absence of studies able to better characterize the safety profile of fusidic acid, it would be preferable to limit the use of this antibiotic during pregnancy and in the subsequent period of breastfeeding exclusively to cases of real need and always under strict supervision by your doctor.

Interactions

There are currently no pharmacologically relevant interactions.

Contraindications DERMOMYCIN ® Fusidic acid

The use of DERMOMYCIN ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients and in patients with rosaceae.